Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (November 2023)
27 slides from Immunome's investor presentation, Nov 15, 2023
Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation November 15, 2023
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Morphimmune, Inc. (“Morphimmune”) and Immunome, Inc. (“Immunome”) or a
Slide 3: Establishing a Preeminent Targeted Oncology Company
Establishing a Preeminent Targeted Oncology Company Long-Term Corporate Vision Strong Foundation for Long-Term Success • Experienced, successful leadership team whose • Develop first-in-class and best-in-class members have developed approved oncology oncology therapies therapeutics across multiple m
Slide 4: Pipeline and Discovery Overview
Pipeline and Discovery Overview Lead Development Anticipated Discovery IND-Enabling Optimization Candidate IND Filing Anti-IL-38 Solid Tumors TBD 177Lu-FAP Solid Tumors 1Q2025 Anti-EPN-1 Solid Tumors TBD ADCs Various TBD RLTs Various TBD Bispecifics Various TBD Novel Antibodies Various TBD IMMUNOME
Slide 5: ADC Strategy
ADC Strategy IMMUNOME 5
Slide 6: Pursuing Novel Targets For the Next Generation of ADCs
Pursuing Novel Targets For the Next Generation of ADCs Active ADC development is concentrated in programs $175m Attractive Opportunity to Pursue Novel Targets against top 10 targets1 • Able to systematically screen for novel targets • Strong interest in ADCs with 8 new drug approvals since 2019 – Di
Slide 7: Immunome ADC Approach: Generate Value Through Advancing Novel Targets
Immunome ADC Approach: Generate Value Through Advancing Novel Targets Novel Targets and Efficient Development Through Clinical Proof of Concept Antibodies Immunome Discovery Platform Optimize Early go/no-go 70+ identified antibody-target pairs Optimization Incorporation Select payload pharmacology d
Slide 8: Strong Demand for ADCs Provides Strategic Flexibility
Strong Demand for ADCs Provides Strategic Flexibility Opportunities to Transact at Value Inflection Points Recent ADC Transactions $170 million upfront3 $2 billion total1 $1.5 billion+ in milestones $4 billion upfront $43 billion $22 billion acquisition in milestones $175 million $85 million upfront
Slide 9: Immunome Discovery Platform
Immunome Discovery Platform IMMUNOME 9
Slide 10: Antibody and Target Discovery Engine
Antibody and Target Discovery Engine Harnessing the Immune System to Inform the Next Generation of Cancer Therapy Patient responses unveil novel disease targets 01 02 03 04 Patients with cancer Memory B cells are Antibodies are selected Novel antibody-target generate memory B cells isolated, and imm
Slide 11: Immunome Approach Identifies Both Validated and Novel Cancer Targets
Immunome Approach Identifies Both Validated and Novel Cancer Targets Identification of Clinically Validated Cancer Immunome Technology Enhances Power Targets Validates Immunome Approach of Antibody Screens • Memory B-cell response generated across course of disease � Competitor B-cell platforms rest
Slide 12: High Throughput Platform Identifies Targets Rapidly Across Multiple Cancer Types
High Throughput Platform Identifies Targets Rapidly Across Multiple Cancer Types Multiple Tumor Catalog at Industrial Robust & Efficient Novel Target Types Scale Screening Discovery 14 140 70 Up to Cancers Libraries 20,000 Antibody-Target Pairs Antibodies Per Screen to Date 350+ ~250k ~2,400 2-4 Tum
Slide 13: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie Key Financial Terms • AbbVie option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types • $30M upfront payment • Eligible for additional payments up to: � $70M platform access payments (in additi
Slide 14: Programs: Anti-IL-38
Programs: Anti-IL-38 IMMUNOME 14
Slide 15: IL-38 Is an Immunosuppressive Cytokine with I/O Potential
IL-38 Is an Immunosuppressive Cytokine with I/O Potential IL-38 Function: Inhibits pro-inflammatory IL-36/IL-36R pathway1 Scientific Rationale: Downregulation of IL-38 promotes innate immune activation • IL-38 knockout mice exhibit increased pro-inflammatory cytokine levels2 and delayed tumor growth
Slide 16: Poor Survival for Cancer Patients with Tumors Expressing High IL-38
Poor Survival for Cancer Patients with Tumors Expressing High IL-38 Reduced Immune Cell Infiltration in IL-38 High Tumors Poor Overall Survival in IL-38 High Lung Cancer Kaplan-Meier curves according to IL-38 expression in patients with primary lung adenocarcinoma IL-38 IHC Stain Intensity Low Mediu
Slide 17: IMM20320: Platform-Derived, Potential First-in-Class Anti-IL-38 mAb
IMM20320: Platform-Derived, Potential First-in-Class Anti-IL-38 mAb Inhibits IL-38-mediated immunosuppression IMM20230 Selectively Binds IL-38 IMM20230 Inhibits IL-38 Binding IMM20320 Inhibits Tumor Growth in Mice 100 5000 1st dose IL-38 2000 Vehicle (mm ) SEM(mm3) 80 3 4000 Anti-CTLA4 - 10 mg/kg IL
Slide 18: Programs: 177Lu-FAP
Programs: 177Lu-FAP IMMUNOME 18
Slide 19: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with FAP imaging shows high expression across Pan-Cancer Potential 15 distinct tumor types • Fibroblast Activation Protein (FAP) is a cell surface protease with low expression in normal tissue • FAP is overexpressed on cancer-associated fibroblasts, the most common tumo
Slide 20: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Immunome Approach Designed and Example Proven structure used by Systematically Screened Pluvicto and Lutathera to Optimized linker deliver Lu-177 isotope Structure: reduces non- specific uptake Chelator FAP Ligand Linker Immunome has systematically select
Slide 21: Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile
Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile and Biodistribution Total Absorbed Dose Rat IV PK 600 100000 Albumin Binding Albumin Binding Weak Weak 10000 500 Moderate concentration Moderate Strong Plasmaconcentration 1000 400 Strong (ng/mL) (ng/mL) mGy/MBq 100
Slide 22: Developing 177Lu-FAP Candidates with Best-in-Class Potential
Developing 177Lu-FAP Candidates with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG Model 177 No Weight Loss Observed Stab Characteristics Potential Best-in-Class 177 Lu-Mi-003 Radiotherapy in U87MG tumors Lu-Mi-003 Radiotherapy in
Slide 23: IP, Business Development, and Leadership
IP, Business Development, and Leadership IMMUNOME 23
Slide 24: Prosecuting a Multi-Layered IP Strategy
Prosecuting a Multi-Layered IP Strategy COMPOSITION OF MATTER • Over 100 patents and patent applications across more than 20 families as of November 2023 • Covers Immunome’s proprietary PLATFORM & DISCOVERY antibody sequences • Platform technologies and • Covers proprietary targeting discovery engin
Slide 25: Immunome Intends to Aggressively Expand Pipeline
Immunome Intends to Aggressively Expand Pipeline $175m $175m Market conditions are challenging for early stage biotechs Immunome takes a flexible approach to pipeline expansion • In-licensing, asset purchase or M&A Oncology IPOs by Year1 • Flexible approach centered on quality data rather than stage
Slide 26: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) President & Chief • Grew company to $2B+ revenue (2022) leading to pending $43B acquisition Executive Officer • Led development of 4 FDA-approved therapeutics • R
Slide 27: Building the Foundation for a Premier Targeted Oncology Company
Building the Foundation for a Premier Targeted Oncology Company • Experienced management team with headquarters in Bothell • Focused on developing best-in-class or first-in-class targeted oncology therapies including next-generation ADCs, RLTs, and naked antibodies • Two lead programs: a potential f